Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04

Vaccine

Volumn 23, Issue 3, 2004, Pages 316-320

  Boland, G ^a   Beran, J ^b   Lievens, M ^c   Sasadeusz, J ^d   Dentico, P ^e   Nothdurft, H ^f   Zuckerman, J N ^g   Genton, B ^h   Steffen, R ⁱ   Loutan, L ^j   Hattum, J Van ^a   Stoffel, M ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b Vaccination and Travel Medicine Centre   (Czech Republic)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF MUNICH   (Germany)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^h POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Adjuvant AS04; Hepatitis B vaccine; Safety

Indexed keywords

ALUMINUM SALT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; PHOSPHORYL LIPID A; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HUMAN; IMMUNOGENICITY; MALE; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; SINGLE-BLIND METHOD;

EID: 20844431695     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.06.006     Document Type: Article

References (14)

1. M.A. Kane, and A. Brooks New immunization initiatives and progress toward the global control of hepatitis B Curr. Opin. Infect. Dis. 15 5 2002 465 469
2. M.A. Kane Global control of primary hepatocellular carcinoma with hepatitis B vaccine: the contributions of research in Taiwan Cancer Epidemiol. Biomarkers Prev. 12 1 2003 2 3
3. D. FitzSimons, G. Francois, N. Emiroglu, and P. Van Damme Combined hepatitis B vaccines Vaccine 21 13-14 2003 1310 1316
4. R. Gupta, and G.R. Siber Adjuvants for human vaccines - current status, problems and future prospects Vaccine 13 1995 1263 1273
5. J.A. Rudbach, K.R. Myers, D.J. Rechtman, and J.T. Ulrich Prophylactic use of mono-phosphoryl lipid A in patients at risk for sepsis Prog. Clin. Biol. Res. 388 1994 107 124
6. Ribi E, Cantrell J, Feldner T. Biological activities of monophosphoryl Lipid A. In: Levine L, Bonventre PF, Morello JA, editors. Microbiology. Washington, DC; 1986. p. 9-13.
7. K.R. Myers, A.T. Truchot, and J. Ward A critical determinant of lipid A endotoxic activity A. Nowotny Proceedings of the first Congress of the International Endotoxin Society on Cellular and Molecular Aspects of Endotoxin Reactions 1990 Elsevier Amsterdam 145 156
8. S. Thoelen, N. De Clercq, and N. Tornieporth A prophylactic hepatitis B vaccine with a novel adjuvant system Vaccine 19 2001 2400 2403
9. Advisory Committee on Immunization Practices. Recommendations for protection against viral hepatitis. MMWR 1990;39:1-26.
10. S. Thoelen, P. Van Damme, and C. Mathei Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system Vaccine 16 1998 708 714
11. F. Ambrosch, G. Wiedermann, and M. Kundi A hepatitis B vaccine formulated with a novel adjuvant system Vaccine 18 2000 2095 2101
12. K. Levie, I. Gjorup, Skinhøj, and M. Stoffel A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B™ in healthy young adults Scand. J. Infect. Dis. 34 8 2002 610 614
13. I. Desombere, G. Leroux-Roels, and M. Van der Wielen HLA DQ2 positive subjects vaccinated with HB-AS04, a hepatitis B vaccine with a novel adjuvant Vaccine 20 2002 2597 2602
14. K. Van Herck, B. Law, and F. Diaz-Mitoma Immunogenicity and reactogenicity of the novel adjuvanted hepatitis B vaccine (HBsAg/SBAS4), compared to that of Engerix-B™ in older adults aged 50-70 years Antiviral Ther. 5 2000 4